Gift Opening
$200 Off MarketBeat All Access
Thanks for being one of our best subscribers! You are eligible for a limited-time discount.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
Claim Your Discount
×
Free Trial
Your confirmation email is on its way. Please check your inbox for further instructions.

These 3 Stocks Are Screaming Oversold: Seize the Opportunity

Germany - April 2, 2024: In this photo illustration,  Micron Technology, Inc.  logo seen displayed on a tablet

Key Points

  • Focusing on oversold stocks with favorable risk-to-reward ratios can be a more rewarding strategy for investors.
  • Oversold stocks can be identified through P/E ratios, RSI readings below 40, or by analyzing price action near crucial support levels.
  • MU, BIIB, and REGN are three stocks that appear oversold and could present substantial buying opportunities for investors seeking recovery plays.
  • 5 stocks we like better than Biogen.

The stock market’s impressive and resilient performance in 2024, with the SPDR S&P 500 ETF NYSE: SPY up over 21% YTD and trading at all-time highs, has led many investors to chase high-flying stocks at all-time highs. However, this approach can be risky as stocks stretched to the upside might face corrections. Instead, focusing on oversold stocks that offer solid risk-to-reward ratios may be more rewarding. 

Identifying oversold stocks can be done using several strategies: valuation metrics like P/E ratios, technical indicators like RSI (with a reading below 40 suggesting oversold conditions), or analyzing a stock’s price action around crucial support levels within a broader uptrend.

Here’s a look at three stocks that appear oversold and may present attractive buying opportunities.

Micron Retraces Following Earnings Beat

Micron Technology, Inc. NASDAQ: MU, a significant player in the semiconductor industry, recently posted a strong earnings beat on September 25th, but shares have since pulled back. After surging to $114.8 following the earnings report, the stock has retraced to $101.7. Despite this pullback, the stock has found support and looks ready to continue its upward trend, presenting an attractive risk-reward opportunity for investors.

Micron Technology MarketRank™ Stock Analysis

Overall MarketRank™
97th Percentile
Analyst Rating
Moderate Buy
Upside/Downside
32.2% Upside
Short Interest Level
Healthy
Dividend Strength
Weak
Environmental Score
-2.35
News Sentiment
0.78mentions of Micron Technology in the last 14 days
Insider Trading
Selling Shares
Proj. Earnings Growth
51.38%
See Full Analysis

In its latest earnings report, Micron posted an EPS of $1.18, beating estimates by $0.21, with revenue of $7.75 billion, up 93.3% year-over-year. This impressive growth signals Micron’s ability to capitalize on the strong semiconductor demand, particularly in artificial intelligence and data centers. Analysts are bullish on the stock, with a Moderate Buy consensus based on 27 ratings, 25 of which are Buy recommendations. The consensus price target of $142.85 represents a potential 40.5% upside, making Micron an enticing pick.

Additionally, with its RSI nearing 40, Micron is approaching oversold territory. Combined with solid fundamentals and analyst optimism, this indicates that the current pullback may be a compelling entry point for long-term investors looking for a potential recovery play in the semiconductor sector.

Biogen Nears Oversold and Undervalued Territory

Biogen Inc. NASDAQ: BIIB, a prominent player in the biotechnology space, has had a challenging year, with its stock down nearly 30% YTD. However, this significant decline has left the stock in both oversold and undervalued territory. Currently trading with an RSI of 36, it might be nearing a potential rebound point. The stock's P/E ratio of 23.4 and forward P/E of 10.82 also suggest a valuation that could attract long-term investors.

Biogen MarketRank™ Stock Analysis

Overall MarketRank™
97th Percentile
Analyst Rating
Moderate Buy
Upside/Downside
47.9% Upside
Short Interest Level
Healthy
Dividend Strength
N/A
Environmental Score
-2.62
News Sentiment
0.41mentions of Biogen in the last 14 days
Insider Trading
Selling Shares
Proj. Earnings Growth
5.51%
See Full Analysis

Biogen reported strong Q2 results, posting an EPS of $5.28, which beat expectations by $1.28, on revenue of $2.47 billion. While revenue growth was modest at 0.4% year-over-year, the stock’s potential upside is catching analysts' attention. Biogen holds a Moderate Buy rating, with analysts forecasting a 47% upside, making it a prime candidate for investors looking to capitalize on a turnaround.

Beyond technical indicators, institutional inflows into the stock further underscore the interest in Biogen as a potential recovery play. Over the past twelve months, inflows have reached $3.57 billion, compared to $2.24 billion in outflows, signaling confidence among institutional investors that the stock’s current valuation might be an attractive entry point.

REGN Finds Support Near Its 200-day SMA

Regeneron Pharmaceuticals, Inc. NASDAQ: REGN, another biotech heavyweight, has pulled back into a critical support level at its rising 200-day simple moving average (SMA), currently near $1,000. The last time the stock hit this major moving average, it surged from $900 to nearly $1,200 within four months. With the stock now trading just above $1,000, history could be about to repeat itself.

Regeneron Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™
93rd Percentile
Analyst Rating
Moderate Buy
Upside/Downside
18.7% Upside
Short Interest Level
Healthy
Dividend Strength
N/A
Environmental Score
-2.69
News Sentiment
0.41mentions of Regeneron Pharmaceuticals in the last 14 days
Insider Trading
Selling Shares
Proj. Earnings Growth
5.24%
See Full Analysis

Regeneron’s Q2 earnings beat estimates by a wide margin, with EPS of $11.56 surpassing estimates by $2.63 and revenue of $3.55 billion, a 12.3% year-over-year increase. The stock’s RSI is now hovering around 30, signaling oversold conditions. With earnings set to be released on October 31, a positive report could propel Regeneron back upward. Analysts are optimistic, with a consensus price target indicating more than 10% upside potential.

Regeneron’s impressive historical performance, robust financials, and strong earnings potential make it a stock to watch as it approaches critical technical support levels. The stock could be poised for a sharp recovery if the company delivers another earnings beat in its upcoming report.

Should you invest $1,000 in Biogen right now?

Before you consider Biogen, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.

While Biogen currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report
Ryan Hasson
About The Author

Ryan Hasson

Contributing Author

Technical Analysis, Momentum Trading, Risk Management

Like this article? Share it with a colleague.

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Micron Technology (MU)
4.8501 of 5 stars
$108.18+1.7%0.43%159.09Moderate Buy$143.04
Regeneron Pharmaceuticals (REGN)
4.6319 of 5 stars
$927.33-0.1%N/A24.56Moderate Buy$1,101.00
Biogen (BIIB)
4.8541 of 5 stars
$183.47-0.8%N/A23.11Moderate Buy$271.39
Compare These Stocks  Add These Stocks to My Watchlist 


Featured Articles and Offers

Palo Alto Networks Gains Momentum: What’s Next for This Cybersecurity Giant?

Palo Alto Networks Gains Momentum: What’s Next for This Cybersecurity Giant?

With earnings on the horizon, will Palo Alto Networks continue its rally through Q4? Find out what analysts and investors are predicting.

Related Videos

3 Momentum Stock Picks With Room to Run

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines